Shots:

• ImaginAb to receive license fees and payments for manufacturing and other support and will supply clinical doses of 89Zr CD8 Immuno-PET agent to Pfizer for use in select oncology clinical trials
• ImaginAb will provide technical- clinical & regulatory support to Pfizer
• The collaboration follows the pre-competitive alliance b/w ImaginAb- Pfizer and other global companies focusing on the development of 89Zr CD8 ImmunoPET technology- signed in Oct 14- 2019

 ­ Ref: PRNewswire | Image: PRNewswire